SCHEMBL737167

SCHEMBL737167

Cc1c(C=O)ccnc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.47
CCR5 P51681 1/20 0.47
CCR8 P51685 1/20 0.47
ALDH1A1 P00352 4/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 3/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
MPI P34949 1/20 0.37
TSHR P16473 1/20 0.37
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
TDP1 Q9NUW8 2/20 0.34
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953596 1.00 CCR1 (0.47) CCR1CCR5CCR8ALDH1A1CYP1A2
SCHEMBL4796219 0.80 CCR1 (0.54) CCR1CCR5CCR8ALDH1A1LMNA
SCHEMBL30529332 0.77 CCR1 (0.50) CCR1CCR5CCR8ALDH1A1CYP1A2
SCHEMBL748190 0.77 CCR1 (0.50) CCR1CCR5CCR8ALDH1A1CYP1A2
SCHEMBL29954640 0.77 CCR1 (0.45) CCR1CCR5CCR8ALDH1A1CYP1A2
SCHEMBL28135507 0.77 TRIM24 (0.53) CCR1CCR5CCR8ALDH1A1LMNA
SCHEMBL29955484 0.77 CCR1 (0.45) CCR1CCR5CCR8ALDH1A1LMNA
SCHEMBL17984974 0.77 NOS2 (0.54) CCR1CCR5CCR8ALDH1A1LMNA
SCHEMBL29956546 0.77 CCR1 (0.45) CCR1CCR5CCR8ALDH1A1LMNA
SCHEMBL24265348 0.74 CCR1 (0.47) CCR1CCR5CCR8ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232109-A PD-1/PD-L1 small molecule inhibitor and application thereof in medicines 广东东阳光药业有限公司 2022-10-25 CN disclosed
EP-2220083-B1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2017-07-19 EP disclosed
US-8138340-B2 Bicyclononene derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-03-20 US disclosed
CN-101010323-B Bicyclononene derivatives as renin inhibitors ACTELION PHARMACEUTICALS LTD 2010-06-16 CN disclosed
EP-1786814-B1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2010-03-31 EP disclosed
US-20090306123-A1 Bicyclononene derivaties ACTELION PHARMACEUTICALS LTD. (CH) 2009-12-10 US disclosed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
EP-2049541-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-04-22 EP disclosed
US-20080234305-A1 Novel Tetrahydropyridine Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-09-25 US disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 WO disclosed
CN-1780663-A 9-azabicyclononene derivatives with a heteroatom in the 3-position as renin inhibitors ACTELION PHARMACEUTICALS LTD (CH) 2006-05-31 CN disclosed
WO-2006021403-A1 BICYCLONONENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 WO disclosed
WO-2006021402-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD. (CH) 2006-03-02 WO disclosed
EP-1622685-A1 9-AZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2006-02-08 EP disclosed
WO-2005054243-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-06-16 WO disclosed
WO-2005054244-A2 AZABICYCLOOCTENE AND OTHER TETRAHYDROPYRIDINE DERIVATIVES WITH A NEW SIDE-CHAIN ACTELION PHARMACEUTICALS LTD (CH) 2005-06-16 WO disclosed
WO-2005040173-A1 DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 WO disclosed
WO-2005040165-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 WO disclosed
WO-2005040120-A1 TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 WO disclosed
WO-2004096366-A1 9-AZABICYCLO’3.3.1!NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306123-A1 Bicyclononene derivaties REN, ACE, CYP51A1 CCR1 1543/4885CCR5 626/4885CCR8 1673/4885
US-20080234305-A1 Novel Tetrahydropyridine Derivatives REN, AGTR1, CBR1 CCR1 401/4885CCR5 1044/4885CCR8 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.